Thrombopoietin receptor (MPL) (MPL)

The Thrombopoietin receptor, also known as MPL or CD110, is a type I cytokine receptor that serves as the master regulator of megakaryopoiesis and platelet production in humans (UniProt P40238). It is primarily expressed on hematopoietic stem cells, megakaryocytic progenitor cells, and mature platelets, where it mediates the biological effects of the hormone thrombopoietin (TPO). Upon ligand binding, the receptor undergoes dimerization and activates intracellular signaling cascades, including the JAK2-STAT, PI3K/Akt, and MAPK pathways, which are essential for the survival, proliferation, and maturation of megakaryocytes into platelets (PubMed: 28935661). The descriptive phrase 'platelet function augmenting' frequently appears in clinical and phytotherapy research to characterize therapeutic agents or herbal extracts that restore platelet counts and enhance hemostatic capacity in patients with bleeding disorders (ResearchGate: 350587422). Pharmacological targeting of this receptor with agonists such as Eltrombopag and Romiplostim is a standard treatment for chronic immune thrombocytopenic purpura (ITP) and aplastic anemia, though its use is associated with risks such as thromboembolism and bone marrow fibrosis (NIH: StatPearls - Thrombocytopenia; FDA: Promacta Label).

Other names

Myeloproliferative leukemia proteinTPO-RCD110Proto-oncogene c-MplPlatelet function augmenting factor (descriptive)

Agonist activity at the thrombopoietin receptor mimics the effect of endogenous thrombopoietin, activating the JAK2-STAT, PI3K/Akt, and MAPK signaling pathways to stimulate the proliferation and maturation of megakaryocytes, thereby increasing platelet production.